ReviewPathology international2026
The Molecular Pathology of Morules in Endometrial Carcinoma: Biological Significance and Clinical Implications.
Review in Pathology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morules were ordinally described as mulberry-like clusters of endometrial metaplasia with the potential to differentiate toward true squamous metaplasia (SqM). Although both morular and SqM lesions are categorized under "endometrial carcinoma (Em Ca) with squamous differentiation" in the WHO classification, they represent biologically distinct entities. Notably, morules are strongly associated with CTNNB1 (β-catenin) mutations. This review summarizes the molecular mechanisms driving the differentiation of Em Ca cells toward both morular and SqM phenotypes. Morules are frequently identified in younger Em Ca patients and display a unique immunophenotype characterized by nuclear β-catenin accumulation, a lack of expression of estrogen-α and progesterone receptor expression, and a low proliferative index. In Em Ca cells harboring CTNNB1 alterations, the PTEN/β-catenin axis suppresses cell proliferation and induces epithelial-to-mesenchymal transition, promoting morule-related cancer stem cell (CSC) properties. Conversely, p40 expression serves as the initial signaling event establishing SqM-related CSC features within the morule-SqM cascade. Furthermore, the ezrin-radixin-moesin-binding phosphoprotein 50/S100A4/myosin heavy chain 9 axis drives terminal squamous differentiation, particularly under hypoxic conditions. Clinically, histopathological evaluation of morular morphology and nuclear β-catenin status serves as a valuable tool for predicting progestin therapeutic efficacy in young Em Ca patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.